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Urothelial carcinoma (UC) originates from the uro-
thelium and accounts for more than 90% of bladder
cancers in Western countries. Upper urinary tract UC
is rare, however, accounting for only 5% of cases of
this disease [1]. Many studies have demonstrated a
preponderance of high-grade and advanced-stage dis-
ease when the upper urinary tract is affected, com-
pared with the lower urinary tract [1–5], though the
mechanisms giving rise to this difference remain un-
clear. The Janus family of tyrosine kinases (JAK) and
the signal transducer and activator of transcription
(STAT) family function in diverse signal transduction
pathways that are involved in cell proliferation, dif-
ferentiation, survival and apoptosis [6]. The results of
numerous studies have supported a role for STAT
proteins, especially STAT3, in oncogenesis [7]. STAT3
is a cytoplasmic latent transcription factor that is per-
sistently tyrosine-phosphorylated by JAK. It can di-
rectly or indirectly up-regulate the expression of genes
required for proliferation and survival of tumor cells.
STAT3 is persistently activated in many human can-
cer cell lines and in a wide variety of hematologic and
epithelial malignancies, including breast, head and
neck, lung, ovarian [7–15] and prostate [12] cancers.
Suppressors of cytokine signaling (SOCS) have been
proposed as negative regulators of cytokine signal-
ing. They have distinct mechanisms of inhibiting the
JAK-STAT pathway as part of a classic feedback loop
[16,17]. The SOCS family consists of eight members,
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In this study, we investigated the expression of phosphorylated signal transducer and activator
of transcription 3 (p-STAT3) Tyr705 and suppressor of cytokine signaling 3 (SOCS3) in urothelial
carcinoma (UC). p-STAT3 (Tyr705) and SOCS3 were analyzed by immunohistochemistry using
tissue microarray and Western blotting. Our results showed that p-STAT3 (Tyr705) was fre-
quently detected in high-grade and infiltrating UC. However, there was no difference in p-STAT3
(Tyr705) staining between UC of the upper and lower urinary tracts. In addition, there was no
significant correlation between expression of SOCS3 and histological differentiation and inva-
siveness of UC. These findings suggest that overexpression of p-STAT3 (Tyr705) occurs in UC,
and that pathways other than SOCS3 may contribute to its activation in this cancer.
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including CIS and SOCS1 through to SOCS7. A previ-
ous study found that deletion of the SOCS3 gene pro-
moted the activation of STAT3 in hepatocytes [18].
However, the relationship between STAT3 and SOCS3
in UC is still poorly understood. In this study, we in-
vestigated the relationships between p-STAT3 (Tyr705)
and SOCS3 expression and clinicopathological fea-
tures in 174 patients presenting with UC, including
51 cases with urinary bladder tumors and 123 with
renal pelvis and ureter tumors.
MATERIALS AND METHODS
Surgical specimens
UC tissue specimens were obtained between 1991 and
2000 from the Department of Surgery at Kaohsiung
Medical University Hospital by biopsy, cystectomy
or nephrectomy. One hundred and seventy-four cases
(80 males and 94 females; mean age, 63.5 years; age
range, 21–81 years) were identified. None of the pa-
tients had received any previous treatment, includ-
ing chemotherapy or radiotherapy. The available fresh
tissue samples were stored at –140°C for Western
blotting analysis, and the residual specimens were
routinely fixed in 10% buffered formalin and embed-
ded in paraffin. Several 5-μm-thick sections were cut
from each tissue specimen. One section from each
specimen was stained with hematoxylin and eosin
for conventional light microscopic analysis, and his-
topathological diagnosis was confirmed by two inde-
pendent pathologists (W.T.H. and C.Y.C.).
Clinicopathologic parameters, including gender,
age, tumor location (upper vs. lower urinary tract),
tumor invasiveness (noninvasive vs. infiltrating) and
histological grade (low grade vs. high grade) were
recorded prospectively (Table 1). Tumor invasiveness
and grade were defined according to the WHO/
International Society of Urologic Pathology 2004.
Tissue microarray construction
The tissue microarray (TMA) was constructed using
formalin-fixed and paraffin-embedded UC tissue sam-
ples. Slides containing a representative area of tumor
were selected and marked with colored ink. For each
case, one core of tumor (2.0mm in diameter) was trans-
ferred from the selected areas to the recipient block.
Serial 5-μm sections of the TMA block were cut and
stained with hematoxylin and eosin to verify that the
cores adequately represented diagnostic areas.
Immunohistochemistry of TMA sections
Immunohistochemistry was performed on 5-μm tis-
sue sections from the TMA blocks. The sections were
placed on slides, deparaffinized, rehydrated, and
then pretreated by autoclave for antigen retrieval.
Table 1. Correlations between expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT3)
Tyr705 and suppressor of cytokine signaling 3 (SOCS3), and clinicopathologic characteristics in urothelial carcinoma
Characteristics
p-STAT3 expression SOCS3 expression
Low, n (%) High, n (%)
p
Low, n (%) High, n (%)
p
Gender 0.474* 0.277*
Male 24 (30.0) 56 (70.0) 15 (18.8) 65 (81.2)
Female 33 (35.1) 61 (64.9) 12 (12.8) 82 (87.2)
Age (yr) 0.308* 0.937*
≤ 67 26 (29.2) 63 (70.8) 14 (15.7) 75 (84.3)
> 67 31 (36.5) 54 (63.5) 13 (15.3) 72 (84.7)
Location 0.416* 0.337*
Upper 38 (30.9) 85 (69.1) 17 (13.8) 106 (86.2)
Lower 19 (37.3) 32 (62.7) 10 (19.6) 41 (80.4)
Tumor invasiveness 0.038* 0.065†
Noninvasive 20 (45.5) 24 (54.5) 3 (6.8) 41 (93.2)
Infiltrating 37 (28.5) 93 (71.5) 24 (18.5) 106 (81.5)
Histological grade 0.000* 0.376†
Low 17 (68.0) 8 (32.0) 2 (8.0) 23 (92.0)
High 40 (26.8) 109 (73.2) 25 (16.8) 124 (83.2)
*χ2 test; †Fisher’s exact test.
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Immunohistochemistry was performed using the fol-
lowing antibodies and dilutions: p-STAT3 (Tyr705)
(Cell Signaling Technology, Beverly, MA, USA) at
dilution 1:75, and SOCS3 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) at dilution 1:75. The DAKO
REAL EnVision Detection System (DAKO, Glostrup,
Denmark) was also used. Finally, tissue sections were
counterstained with Mayer’s hematoxylin. Negative
controls were obtained by replacing the primary anti-
body with non-immune serum.
Scoring of antibody staining
The TMA slides were evaluated twice at different times
by two investigators blinded to the clinical charac-
teristics and survival data. The results for nuclear 
p-STAT3 (Tyr705) staining were assigned based on the
intensity grade [19]. The intensity grade represented
the average nuclear staining intensity of positive
tumor cells (grade 1: minimal staining; grade 2: weak
staining; grade 3: moderate staining; grade 4: strong
staining). Cytoplasm immunostaining intensity results
were also divided into four grades for SOCS3 (grade
1: minimal staining; grade 2: weak staining; grade 3:
moderate staining; grade 4: strong staining). The rare
cases with discordant scores were re-evaluated and
scored on the basis of consensual opinion.
Western blot analysis
All fresh tissue samples were washed in phosphate-
buffered saline (PBS) and extracted in PBS containing
50 mM/L Tris-HCl (pH 7.4), 150 mM/L NaCl, 10 g/L
Triton X-100, 1 g/L sodium dodecyl sulfate (SDS),
1 mM/L EDTA, 1 mM/L AEBSF, and 20 μg/L leu-
peptin. Equal amounts of protein, as determined by
Bradford assay (Bio-Rad, Hercules, CA, USA), were
separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), followed by electroblotting onto a polyvi-
nylidene-difluoride membrane. The membranes were
blocked with 5% non-fat dried milk in Tris-buffered
Saline (pH 7.4) with Tween-20, and then incubated
with either anti-phospho-STAT3 (Tyr705) (1:1,000
dilution; Cell Signaling Technology) or SOCS3 rabbit
polyclonal primary antibody (Santa Cruz Biotechnol-
ogy Inc.). Secondary antibody was conjugated with
horseradish peroxide (Santa Cruz Biotechnology
Inc.). Protein bands were detected by chemilumines-
cence (Amersham, Buckinghamshire, UK). The anti-
GADPH rabbit polyclonal antibody (Cell Signaling
Technology) was used as an internal control.
Statistical analysis
The intensities of p-STAT3 nuclear staining and SOCS3
cytoplasmic staining were further classified into low
expression (grade 1/2) and high expression (grade
3/4) before statistical evaluation. The correlations
between p-STAT3 (Tyr705) expression and SOCS3
expression, and histopathological grade and inva-
siveness of UC were measured using χ2 or Fisher’s
exact tests. All analyses were performed using SPSS
version 12.0 (SPSS Inc., Chicago, IL, USA). A p value
of < 0.05 was considered statistically significant.
RESULTS
Expression profiles of p-STAT3 (Tyr705) and
SOCS3 in UC
p-STAT3 (Tyr705) staining was predominantly de-
tected in the nucleus of neoplastic urothelial cells,
and cytoplasmic staining was minimal (Figures 1A
and 1B). The expression of p-STAT3 in normal urothe-
lium was negative (Figure 1A insert). High-grade UC
exhibited a higher p-STAT3 (Tyr705) intensity grade
than low-grade UC (p < 0.0001). Comparing infiltrat-
ing and noninvasive UC, 20 out of 44 noninvasive
UCs showed a low-intensity p-STAT3 (Tyr705) grade,
while 93 out of 130 infiltrating UCs revealed a high-
intensity grade. There was a significant correlation
between p-STAT3 (Tyr705) intensity grade and inva-
siveness (p = 0.038) (Table 1). The p-STAT3 (Tyr705)
intensity grades were similar in tumors of the upper
and lower urinary tracts (p = 0.416) (Table 1). In ad-
dition, SOCS3 staining was diffuse in the cytoplasm
of the urothelial cells (Figures 1C and 1D). There was
no correlation between grade and invasiveness and
SOCS3 expression (p=0.376 and p=0.065, respectively)
(Table 1). The SOCS3 intensity grades were similar 
in the upper and lower urinary tracts (p = 0.337)
(Table 1). The clinical characteristics are shown in
Table 1. There were no statistically significant corre-
lations between p-STAT3 (Tyr705) or SOCS3 expres-
sion and either gender or age.
Correlation between p-STAT3 
(Tyr705) expression and SOCS3 
expression in UC
Comparing p-STAT3 (Tyr705) expression and SOCS3
expression, it can be seen that 10 out of the 57 
tumors with low-grade SOCS3 expression also showed 
low-grade expression of p-STAT3 (Tyr705), and 100
out of 117 tumors with high-grade p-STAT3 expres-
sion also demonstrated high-grade SOCS3 expres-
sion. There was no significant correlation between
p-STAT3 (Tyr705) and SOCS3 expression (p = 0.606)
(Table 2).
Western blotting
Western blot analysis of p-STAT3 (Tyr705) and SOCS3
protein expression showed markedly elevated p-
STAT3 (Tyr705) expression in high-grade UC. p-STAT3
(Tyr705) expression was low in low-grade UC. How-
ever, there was no correlation between SOCS3 protein
expression and tumor grade (Figure 2). The intensi-
ties of p-STAT3 (Tyr705) expression measured by
densitometer were 0.45 in low-grade UC and 116.65
in high-grade UC. The relative intensities of SOCS3
expression in low- and high-grade UCs were 618.84
and 615.40, respectively.
DISCUSSION
STAT3 is ubiquitously expressed in most tissues.
Ligand-dependent activation of STAT3 is a transient
process in normal cells, lasting for several minutes 
to several hours. In many cancerous cell lines and
tumors, however, STAT3 protein is persistently 
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Figure 1. Immunohistochemical staining of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) Tyr705 and
cytokine signaling 3 (SOCS3) in urothelial carcinomas. Nuclear staining of p-STAT3 (Tyr705): (A) low intensity grade (insert in A is
normal urothelium); (B) high intensity grade. Cytoplasmic staining of SOCS3: (C) low intensity grade; (D) high intensity grade.
Original magnification, 400×.
Table 2. Correlations between the expression of phos-
phorylated signal transducer and activator of trans-
cription 3 (p-STAT3) Tyr705 and suppressor of cytokine
signaling 3 (SOCS3) in urothelial carcinoma
SOCS3
p-STAT3 expression, 
n (%) p*
expression
Low High
Low 10 (17.5) 47 (82.5)
0.606
High 17 (14.5) 100 (85.5)
*χ2 test.
tyrosine-phosphorylated or activated. The abnormal,
persistently activated STAT3 protein can mediate
transformation [20]. Thus, STAT3 is capable of regu-
lating cell proliferation and survival [21]. Numerous
studies have investigated the clinical and biological
significances of p-STAT3 (Tyr705) in human malig-
nancies, and STAT3 has been implicated in the inva-
siveness and metastasis of certain types of cancers,
such as ovarian cancer [22] and renal cell carcinoma
[23]. However, to the best of our knowledge, there
has been no previous report on p-STAT3 (Tyr705)
expression in UC. In the current study, we investi-
gated whether infiltrating UC had higher p-STAT3
expression than noninvasive UC, and determined that
high-grade UC expressed higher levels of p-STAT3
than low-grade UC. Taken together, the expression
level of p-STAT3 (Tyr705) was closely associated with
the invasiveness and degree of differentiation of UC.
Although the clinical features of upper urinary tract
UC are distinct from those in the urinary bladder, no
conspicuous differences in p-STAT3 (Tyr705) expres-
sion were found between tumors from the upper and
lower urinary tracts.
SOCS protein, which is stimulated by several cyto-
kines, such as growth hormone, prolactin, interleukins
and insulin, is a negative feedback regulator that in-
hibits the JAK/STAT pathway [24,25] and promotes
their degradation via the proteasome pathway. Some
reports have indicated that SOCS3 plays an essential
role as a negative regulator in STAT activation [16].
Nevertheless, control of the physiological processes of
SOCS3 has been found to differ between species and
tissues, possibly due to differences between in vitro and
in vivo experiments [26]. In this study, we assessed
SOCS3 protein expression in UCs of the upper and
lower urinary tracts. However, there were no signifi-
cant correlations between SOCS3 expression and inva-
siveness or histological grade of UC. We speculated
that p-STAT3 (Tyr705) expression would be negatively
associated with SOCS3 expression. However, no sig-
nificant correlation between p-STAT3 (Tyr705) and
SOCS3 expression was detected in our investigation.
More than 90% of UC occurs in the urinary blad-
der in western countries. Nevertheless, the occur-
rence of upper UC is uncommonly high in Taiwan
[27]. Owing to its infrequency, few studies have
investigated the molecular indicators of UC in the
upper urinary tract, such as p53 mutation [28], epi-
dermal growth factor receptor or ErbB2 [29]. The 
conclusions have been controversial to date, because
of the limited number of cases. In this study, 123
upper UCs and 51 bladder UCs were analyzed. The
p-STAT3 (Tyr705) intensity grade was significantly
associated with histological grade and invasiveness
of UC. However, there was no significant difference
in p-STAT3 (Tyr705) expression between the upper
and lower urinary tracts. Our results indicate that
altered p-STAT3 (Tyr705) expression in UC is corre-
lated with histological grade and invasiveness. Some
reports have suggested that STAT3 activation is sup-
pressed by SOCS3 protein, but there was no sig-
nificant correlation between p-STAT3 (Tyr705) and
SOCS3 in our study. We therefore suggest that other
pathways may contribute to the activation of STAT
protein and that p-STAT3 (Tyr705) may have devel-
oped strategies to overcome negative regulation by
SOCS3 protein.
In conclusion, we suggest that increased phos-
phorylation of STAT3 may be associated with inva-
siveness and degree of histological differentiation 
in UC. However, no association between p-STAT3
(Tyr705) and SOCS3 was detected in our study.
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Figure 2. Western blotting of phosphorylated signal transducer
and activator of transcription 3 (p-STAT3) Tyr705 and cytokine
signaling 3 (SOCS3) protein in low-grade and high-grade UCs.
p-STAT3 (Tyr705) expression was low and high in low- and
high-grade UCs, respectively. Lane 1 = low-grade UC; lane
2 = high-grade UC. However, the expression of SOCS3 was simi-
lar in low- and high-grade UCs. GADPH protein expression was
used as an internal control.
p-STAT3 (Tyr705)
SOCS3
GADPH
1 2
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基礎醫學研究所
訊息傳導子和轉錄激活子 3 (signal transducer and activator of  transcription 3 , 
STAT3)， 在 人 類 的 數 種 癌 症 中， 已 證 明 酪 氨 酸 705 有 持 續 被 磷 酸 化 
(phosphorylation) 的現象，也因此 STAT3被認為是一種致癌基因。而細胞素傳導
抑制因子 (suppressor of  cytokine signaling 3, SOCS3 ) 則被認為可阻止 STAT3
的磷酸化，扮演負向調控 (negative control) STAT3的角色。本研究的目的是探討泌
尿道上皮癌的 p-STAT3 (Tyr705) 和 SOCS3表現與泌尿道上皮癌之分化程度及侵襲
性的關係。結果顯示，p-STAT3 (Tyr705) 在分化較差及具侵襲性的泌尿道上皮癌
中，的確出現較高的表現強度以及染出比例，而 SOCS3並未出現顯著相關。
關鍵詞：免疫組織化學染色，訊息傳導子和轉錄激活子 3 ，細胞素信號傳導抑制因子，泌尿道上皮癌
(高雄醫誌 2009;25:640–6)
